Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Checkpoint inhibitor–induced rheumatic complications have unique features

Publish date:: June 19, 2019

Key clinical point: In a detailed evaluation of 10 patients, the musculoskeletal complications of checkpoint inhibitors were found to be unique.

Major finding: Myositis is more common than synovitis, but range of motion is preserved even with an otherwise large symptom burden.

Data source: A prospective analysis of 10 consecutive patients.

Disclosures: Dr. Filippopoulou reported no potential conflicts of interest.

Citation:

Filippopoulou A et al. Ann Rheum Dis. Jun 2019;78 (Suppl 2):251. Abstract OP0335. doi: 10.1136/annrheumdis-2019-eular.5029.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Immunotherapy

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Personalized cancer vaccine may enhance checkpoint inhibitor activity,

New registry focuses on rheumatic immune-related AEs of cancer therapy,

Tumor neoantigenicity metric improves prediction of response to immunotherapy,

New Toxicity Subscale Measures QOL in Cancer Patients on Checkpoint Inhibitors,